<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194439</url>
  </required_header>
  <id_info>
    <org_study_id>1405976232</org_study_id>
    <secondary_id>1R01HD074587-01</secondary_id>
    <nct_id>NCT02194439</nct_id>
  </id_info>
  <brief_title>Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease</brief_title>
  <official_title>Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to collect longitudinal biological samples from patients after
      hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers
      to validate biomarkers of both acute and chronic GVHD as well as for use in future
      unspecified research. The centers include Dana-Farber Cancer Institute and Boston's
      Children's Hospital, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred Hutchinson
      Cancer Research Center, Texas Children's Hospital, Children's National Medical Center, and
      Indiana University Simon Cancer Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent is signed, this study will involve 1) collection of basic HCT data and
      clinical data available in the medical record and 2) providing blood (and saliva in
      occasional cases) samples for processing, storage, DNA extraction, and analysis (including a
      seven biomarker protein panel as well as future unspecified research purposes).

      Pediatric and adult patients will be included (all adult patients will be from the Fred
      Hutchinson Cancer Research Center, the Johns Hopkins Sidney Kimmel Comprehensive Cancer
      Center, and the Indiana University Simon Cancer Center).

      Primary Objective:

      1. To confirm that ST2 alone or the seven-biomarker panel measured at initiation of GVHD
      therapy predict a) D180 post-therapy non-relapse mortality; b) D28 post-therapy non-response,
      and c) GVHD grade 1-4 onset D180 post-therapy non-relapse mortality.

      Secondary Objective:

        1. To demonstrate that ST2 alone or the seven-biomarker panel measured at day 14 or day 21
           post-HCT (or a combination of these time points) predicts D180 post-HCT non-relapse
           mortality.

        2. To demonstrate that ST2 alone or the seven-biomarker panel measured at initiation of
           GVHD symptoms/therapy diagnose acute GVHD as compared to other complications presenting
           with similar symptoms (drug rash, CMV, Clostridium enteritis).

        3. To demonstrate that ST2 alone or the seven-biomarker panel measured at initiation of
           GVHD symptoms/therapy diagnose the severity of acute GVHD at onset and maximum.

        4. To develop a repository of biospecimens linked to clinical data for future unspecified
           research.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm Biomarkers Predictive Efficacy</measure>
    <time_frame>2 years</time_frame>
    <description>To confirm the efficacy of ST2 alone or the seven-biomarker panel when measured at the initiation of GVHD therapy to predict:
6 month post-therapy non-relapse mortality
D28 post-therapy non-response
GVHD grade 1-4 onset 6 month post-therapy non-relapse mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate Efficacy of Biomarkers to Predict Non-Relapse Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>To demonstrate the efficacy of ST2 alone or the seven-biomarker panel measured at day 14 or day 21 post-HCT (or a combination of these time points) to predict 6 month post-HCT non-relapse mortality.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Demonstrate Efficacy of Biomarkers to Diagnose GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>To demonstrate the efficacy of ST2 alone or the seven-biomarker panel measured at initiation of GVHD symptoms/therapy to diagnose GVHD as compared to other complications presenting with similar symptoms (drug rash, CMV, Clostridium enteritis).</description>
  </other_outcome>
  <other_outcome>
    <measure>Demonstrate Efficacy of Biomarkers to Diagnose Severity of GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>To demonstrate the efficacy of ST2 alone or the seven-biomarker panel measured at initiation of GVHD symptoms/therapy to diagnose the severity of acute GVHD at onset and maximum.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>hematopoietic stem cell transplant</arm_group_label>
    <description>procedure</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, Plasma, Peripheral Blood Mononuclear Cells (PBMC), Saliva, Bronchoalveolar
      lavage (BAL)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients receiving an allogeneic hematopoietic stem cell transplant, cord blood transplant,
        bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion (DLI), or donor
        cellular infusion (DCI) from Dana-Farber Cancer Institute and Boston Children's Hospital,
        Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred Hutchinson Cancer Research
        Center, Texas Children's Hospital, Children's National Medical Center, and Indiana
        University Simon Cancer Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: - All patients receiving an allogeneic hematopoietic stem cell
        transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor
        lymphocyte infusion (DLI), or donor cellular infusion (DCI) can be included.

        Exclusion Criteria: - patients not receiving an allogeneic hematopoietic stem cell
        transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor
        lymphocyte infusion (DLI), or donor cellular infusion (DCI) will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Paczesny, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Unversity Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Sophie Paczesny</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Immunology</investigator_title>
  </responsible_party>
  <keyword>Acute Graft Versus Host Disease</keyword>
  <keyword>Affect</keyword>
  <keyword>Anti-inflammatory</keyword>
  <keyword>Anti-inflammatory Agents</keyword>
  <keyword>Antigen-Presenting Cells</keyword>
  <keyword>Alloantigen</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Allograft rejection</keyword>
  <keyword>Allograft Tolerance</keyword>
  <keyword>Antigens</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Biospecimen Repository</keyword>
  <keyword>BMT</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Cell Transplantation</keyword>
  <keyword>Cells</keyword>
  <keyword>Clonal Expansion</keyword>
  <keyword>Complex</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Data</keyword>
  <keyword>Development</keyword>
  <keyword>Environment</keyword>
  <keyword>Failure (biologic function)</keyword>
  <keyword>Genomics</keyword>
  <keyword>Graft-vs-Host Disease</keyword>
  <keyword>Graft-vs-Leukemia</keyword>
  <keyword>GVHD</keyword>
  <keyword>GVL</keyword>
  <keyword>Hematopoietic</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>HCT</keyword>
  <keyword>HSCT</keyword>
  <keyword>IL-33 Receptor</keyword>
  <keyword>Immune Reconstitution</keyword>
  <keyword>Immune Response</keyword>
  <keyword>Inflammatory</keyword>
  <keyword>Modeling</keyword>
  <keyword>Novel</keyword>
  <keyword>Novel therapeutics</keyword>
  <keyword>Outcome</keyword>
  <keyword>Pathway interactions</keyword>
  <keyword>Peptides</keyword>
  <keyword>Prevent</keyword>
  <keyword>Process</keyword>
  <keyword>Production</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Regulatory T-Lymphocyte</keyword>
  <keyword>Response</keyword>
  <keyword>Role</keyword>
  <keyword>Signal</keyword>
  <keyword>ST2</keyword>
  <keyword>Transduction</keyword>
  <keyword>T-cell response</keyword>
  <keyword>T-cell Activation</keyword>
  <keyword>T-Lymphocytes</keyword>
  <keyword>Tissues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

